HiPay Group : HiPay Appoints Grégoire Bourdin as Chief

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
HiPay Group : HiPay Appoints Grégoire Bourdin as Chief Executive Officer

HiPay Appoints Grégoire Bourdin as Chief Executive Officer

Paris, 15 November 2016, 07:00 a.m. -  HiPay Group (Code ISIN FR0012821916 - HIPAY), the Fintech company specialized in online payments, today announced that Grégoire Bourdin has been appointed as Chief Executive Officer, effective 15 December 2016.

Following his experience in audit at KPMG, Grégoire Bourdin, 37, served as Chief Financial Officer at HiMedia from 2008 to 2011 where he restructured financial operations, supervised all French and foreign subsidiaries, and accompanied the integration of acquired companies.

In 2012, he joined Benjamin Jayet with whom he led a dynamic investment strategy and coordinated numerous operations. Expert in the digitization of the banking sector and passionate about new models developed by Fintech, Grégoire Bourdin founded Treezor in 2014, under the aegis of BJ Invest.

Loïc Jauson, Chief Executive Officer of BJ Invest, will now represent BJ Invest on the HiPay Board of Directors.  Combining his entrepreneurial experience with the creation and growth of several digital companies, Loïc Jauson has developed expertise in online payment services like those implemented by HiPay Mobile. He then co-led Prosodie Group's publishing business for seven years before joining Benjamin Jayet to support him in the development and growth of his group, where he has been the CEO since 2010.

Gabriel de Montessus will step down from the position of CEO of HiPay on December 15, 2016, after a transition period. The financial conditions of his departure are communicated in accordance with the legal provisions.

Commenting on the nomination, Benjamin Jayet, Chairman of the Board, said: " I am delighted to welcome Grégoire as the new CEO of HiPay. His arrival completes the management restructuring started in May. He brings both passion and a considerable amount of experience in the European payments sector. The Board of Directors and I give him our full support to implement our growth strategy and to contribute to the development of shareholder value for the company.  I would like to thank Gabriel for his tireless commitment in recent years, his undeniable contribution to the success of HiPay, and for the strategic initiatives he has launched. They laid the foundation for the development of HiPay. "

Grégoire Bourdin added: " HiPay, with €2 billion in annual run rate on its platform, is a very promising European Fintech and I am very pleased to have the opportunity to lead this group at such an important moment. In close collaboration with the HiPay team and Benjamin Jayet, I will be committed to pursuing international development, strengthening our technological innovations and structuring the product portfolio. "

Next financial communication: 16 February 2017 - 2016 Revenue.

About HiPay Group

We're a global payment provider processing more than 2bn € annually across 150 countries and 220 payment types. By harnessing data analytics, we help deliver valuable customer insights that enable our clients' businesses to succeed.

More information on hipay.com Find us on Twitter , LinkedIn and Google+

HiPay Group is listed on the Euronext Paris Compartment C (ISIN code: FR0012821916 / Mnemo: HIPAY).

Citigate Dewe Rogerson

Daiana Hirte (Press) +33 (0)1 53 32 78 90 daiana.hirte@citigate.fr

Antoine Denry (Relations Investisseurs) +33 (0)1 53 32 78 95 antoine.denry@citigate.fr

This press release does not constitute an offer to sell or a solicitation of an offer to buy HiPay Group shares. If you wish to obtain more information about HiPay Group, please refer to our website hipay.com , under the Investors heading. This press release may contain some forward-looking statements. Although HiPay Group considers that these statements are based on reasonable statements on the publication date of this release, they are by their very nature subject to risks and uncertainties that could cause the actual results to differ from those indicated or projected in these statements. HiPay Group operates in a continually changing environment and new risks could potentially emerge. HiPay Group assumes no obligation to update these forward-looking statements, whether to reflect new information, future events or other circumstances.

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...53e8eb3610

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 29

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 23

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 17

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 16

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 22

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 23

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Context Therapeutics Gains Confidence with Strategic Developments

Updated Category News Views 60

Piper Sandler's Renewed Confidence in Context Therapeutics Piper Sandler has reiterated an Overweight rating for Context Therapeutics (NASDAQ: CNTX), maintaining a price target of $4.50 for the stock. This endorsement underscores their belief in the company’s potential within the biopharmaceutical sector. Positive Data from Competitors Enhances Expectations This renewed...

Continue Reading
Actinium's ATNM-400: A Promising Frontier in Prostate Cancer Therapy

Updated Category News Views 167

Introduction to ATNM-400's Innovative Approach Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has announced compelling preclinical data showcasing its innovative treatment, ATNM-400. This first-in-class antibody radioconjugate targets a unique, non-PSMA antigen, revolutionizing prostate cancer therapy. ATNM-400 offers noteworthy therapeutic activity independent of...

Continue Reading
Opportunity Knocks: Ligon's Major Auction Up for Bids

Updated Category News Views 17

Equipment Auction Offers Unique Buying Opportunity Catch this: Ligon Co.'s auction is like finding a needle in a haystack in a world of overpriced equipment. We're talking about a smorgasbord of heavy machinery up for online grabs, and it’s happening until June 17. Auction Highlights: Your Next Business Asset? From telehandlers to trailers, this ain't your everyday yard...

Continue Reading
Selector Enhances Service Delivery with AWS Marketplace Launch

Updated Category News Views 147

Selector Launches on AWS Marketplace for Better Accessibility Selector, a pioneer in AI-driven observability and network intelligence, is transforming how organizations manage their network operations. The company has launched its flagship platform on the Amazon Web Services (AWS) Marketplace, which makes it easier for customers to procure and deploy its powerful AI tools...

Continue Reading
Exploring the Surge in Decentralized Energy Storage Growth

Updated Category News Views 229

Decentralized Energy Storage Market Overview The Decentralized Energy Storage market is gaining remarkable traction, with significant insights indicating a shift towards sustainable energy solutions. Valued at approximately USD 10.88 billion, the market is anticipated to expand to a staggering USD 35.62 billion, exhibiting a compound annual growth rate (CAGR) of 15.98%...

Continue Reading